Scientific Publications
Nazma's research is devoted to the innovation of natural nano-based systems, employing extracellular vesicles and cell-derived nanoparticles. She focuses on leveraging these systems to transport therapeutic proteins directly to target cells, striving to forge more efficient and safer drug delivery mechanisms for gene therapy. Her work is poised to transform medical practices and improve treatment methodologies for a range of genetic conditions. Nazma's contributions are pivotal to the advancement of targeted medication delivery, potentially leading to significant developments in gene therapy.
TOP-EVs: Technology Of Protein Delivery Through Extracellular Vesicles Is A Versatile Platform For Intracellular Protein Delivery
Most EV-based engineered loading methods have a limited delivery efficiency owing to their inefficient endosomal escape or cargo release from the intraluminal attachment from the EV membrane. Here, we describe the ‘Technology Of Protein delivery through Extracellular Vesicles’ (TOP-EVs) as a tool for efficient intracellular delivery of target proteins mediated via EVs
JOURNAL OF CONTROLLED RELEASE 355, 579-592
Extracellular vesicle-mediated delivery of CRISPR/Cas9 ribonucleoprotein complex targeting proprotein convertase subtilisin-kexin type 9 (Pcsk9) in primary mouse hepatocytes
The loss‐of‐function of the proprotein convertase subtilisin–kexin type 9 (Pcsk9) gene has been associated with significant reductions in plasma serum low‐density lipoprotein cholesterol (LDL‐C) levels. We investigated EV-mediated RNP targeting of the Pcsk9 gene ex vivo in primary mouse hepatocytes.
JOURNAL OF EXTRACELLULAR VESICLES 13 (1), 12389
Extracellular Vesicle-Mediated Protein Delivery To The Liver
EVs are regarded as a promising natural drug delivery system for transporting and delivering bioactive macromolecules to target cells. To the best of our knowledge, this is the first study to simultaneously investigate the tissue distribution of FKBP12/FRB-engineered EVs and their subsequent intracellular protein delivery in Ai9 Cre-loxP reporter mice.
JOURNAL OF EXTRACELLULAR BIOLOGY 2 (9), E9
Enabling Precision Medicine With CRISPR-Cas Genome Editing Technology: A Translational Perspective
Genome editing technologies, particularly CRISPR-Cas (clustered regularly interspaced short palindromic repeats (CRISPR) associated nucleases), are redefining the boundaries of therapeutic gene therapy. Despite its high therapeutic potential, CRISPR-Cas´ clinical translation is still in its infancy and is highly dependent on its efficiency, specificity in gene corrections, and cell-specific delivery.
GENOME EDITING IN CARDIOVASCULAR AND METABOLIC DISEASES, 315-339
Biofabrication Of Cell-Derived Nanovesicles: A Potential Alternative To Extracellular Vesicles For Regenerative Medicine
Extracellular vesicles (EVs) are mediators of intercellular communication by transferring functional biomolecules from their originating cells to recipient cells. This intrinsic ability has gained EVs increased scientific interest in their use as a direct therapeutic in the field of regenerative medicine or as vehicles for drug delivery.
CELLS 2019, 8(12), 1509
